RxDoctor Payments Data

Madonna Fabian

Internal Medicine · St Joseph, MINPI 1124438411

Payments from drug & device makers

$2,713in general payments, 2019–2025

Across 99 payments — averaging $27.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$703
  • Novo Nordisk$421
  • AbbVie$300
  • Corcept Therapeutics$259
  • Bayer$145
  • Boston Scientific$102
  • plus $783 from 17 others

What the payments were for

  • Food & beverage$2,68499%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,713 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$38,821
Medicare patients
103
Services billed
434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol12$17,183
MounjaroTirzepatide12$12,314
OzempicSemaglutide13$12,262
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,034
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,517
Atorvastatin Calcium61$977
Levothyroxine Sodium45$687
Amlodipine Besylate56$498
Losartan Potassium35$404
Lisinopril44$393
Metoprolol Succinate21$344
Cefpodoxime Proxetil11$333
ClopidogrelClopidogrel Bisulfate14$298
Metformin Hcl39$295
Omeprazole22$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$703$17,18312 claims
Lilly USA, LLCMounjaro$21$12,31412 claims
Novo NordiskOzempic$421$12,26213 claims
GSKAnoro Ellipta$33$5,03411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in St Joseph

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →